An avelumab combination therapy shows promise against ALK-driven lung cancers, but another was neither safe nor effective in non–ALK-driven cases.
Researchers in Hong Kong found dacomitinib was associated with longer OS than gefitinib in patients with advanced EGFR+ NSCLC.
“Now that effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize a risk/benefit ratio is crucial,” emphasizes lead author Max Madu.
Weekly patient symptom self-reports, filed using an online tool, allowed timely detection of lung cancer relapses and prolonged patient survival.
The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB–IVM1a melanoma.
Corticosteroid medications are associated with poorer outcomes of therapy with immune checkpoint inhibitors for patients with lung cancer.
In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia.
Overall, patients with mCRC and isolated peritoneal carcinomatosis did not benefit when hyperthermic intraperitoneal chemotherapy was added to surgery.
In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenström macroglobulinemia.
Patients treated for RCC with atezolizumab plus bevacizumab reported fewer impacts to daily function and quality of life than those on sunitinib.